Oxford Cannabinoid Tech.Holdings New Broker and Investor Presentation (5218L)
May 16 2022 - 2:01AM
UK Regulatory
TIDMOCTP
RNS Number : 5218L
Oxford Cannabinoid Tech.Holdings
16 May 2022
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or "the Company")
Appointment of Axis Capital Markets as Corporate Broker
&
Notice of Investor Meet Company Live Q&A Session
Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical
company developing prescription cannabinoid medicines targeting the
US$ multi-billion pain market, is pleased to announce the
appointment of Axis Capital Markets Limited ("AxCap") as the
Company's corporate broker with immediate effect ( www.axcap247.com
).
AxCap will work alongside OCTP's existing financial adviser,
Cairn Financial Advisers LLP.
Investor Meet Company Q&A Session, 4:30 p.m., 30 May
2022
The Company is also pleased to announce that it will be hosting
a live online Q&A session via the Investor Meet Company
platform at 4:30 p.m. BST on 30 May 2022, which is open to all
existing and potential shareholders.
Questions can be submitted pre-event via the 'Investor Meet
Company' dashboard up until 9:00 a.m. on Friday 27 May 2022 or at
any time during the live presentation. Investors can sign up to
Investor Meet Company for free via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
Investors who already follow OCTP on the Investor Meet Company
platform will automatically receive an invitation to the event. The
Company will also use this opportunity to respond to questions
already received.
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0)20 7213 0885
Axis Capital Markets Limited +44 (0)20 3026 0320
Kamran Hussain
Richard Hutchison
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann/Nick Rome +44 (0)7768 807631
oxcantech@walbrookpr.com
Harbor Access LLC
Richard Leighton/Jonathan Paterson +1 (475) 455 9403
Richard.Leighton@HarborAccessllc.com
About Oxford Cannabinoid Technologies Holdings plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a
pharmaceutical company developing prescription cannabinoid
medicines for approval by key medicines regulatory agencies
worldwide and targeting the U$ multi-billion pain market (together
the "Group"). Cannabinoids are compounds found in the cannabis
plant that have been shown to have a range of therapeutic effects
on the body, including pain relief. The Group has a clearly defined
path to commercialisation, revenues and growth. The Group is
developing drug candidates through clinical trials to gain
regulatory approval (FDA/MHRA/EMA) that will enable medical
professionals to prescribe them with confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with clinical trials scheduled for Q1 2023. The Group's
product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of
rare diseases and includes chemically modified phytocannabinoids
with improved drug-like characteristics and a proprietary library
of cannabinoids.
OCTP operates a partnership model with external academic and
commercial partners.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFVDEAIVLIF
(END) Dow Jones Newswires
May 16, 2022 02:01 ET (06:01 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Sep 2023 to Sep 2024